Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ed Clarke

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
The Lancet. Infectious Diseases|January 31, 2021
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trialEd Clarke, Adedapo Bashorun, Ikechukwu Adigweme, et al.
The Lancet. Infectious Diseases|January 18, 2024
Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort studyAdedapo O Bashorun, Larry Kotei, Ousubie Jawla, et al.
Lancet (London, England)|February 25, 2024
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trialMagnus Ochoge, Ahmed Cherno Futa, Ama Umesi, et al.
The Lancet. Global Health|July 2, 2016
Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The GambiaEd Clarke, Yauba Saidu, Jane U Adetifa, et al.
Lancet (London, England)|May 2, 2024
A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trialIkechukwu Adigweme, Mohammed Yisa, Michael Ooko, et al.
Gates Open Research|March 29, 2023
Circulation of respiratory viruses during the COVID-19 pandemic in The GambiaSheikh Jarju, Elina Senghore, Helen Brotherton, et al.
Cell Reports. Medicine|January 14, 2022
Prior upregulation of interferon pathways in the nasopharynx impacts viral shedding following live attenuated influenza vaccine challenge in childrenAndré G Costa-Martins, Karim Mane, Benjamin B Lindsey, et al.
Vaccine|December 27, 2025
Maternal iron status and total immunoglobulin-G influence transplacental antibody transfer across eight diverse geographical settingsKaren S Tiley, Hinke Ten Hulscher-van Overbeek, Andrew E Armitage, et al.
Cell Reports. Medicine|March 4, 2022
Erratum: Prior upregulation of interferon pathways in the nasopharynx impacts viral shedding following live attenuated influenza vaccine challenge in childrenAndré G Costa-Martins, Karim Mane, Benjamin B Lindsey, et al.
The Lancet. Microbe|January 20, 2025
Interactions between live attenuated influenza vaccine and nasopharyngeal microbiota among children aged 24-59 months in The Gambia: a phase 4, open-label, randomised controlled trialChikondi Peno, Ya Jankey Jagne, Melanie Clerc, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The Lancet. Infectious Diseases|January 31, 2021
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trialEd Clarke, Adedapo Bashorun, Ikechukwu Adigweme, et al.
The Lancet. Infectious Diseases|January 18, 2024
Tolerability, safety, and immunogenicity of the novel oral polio vaccine type 2 in children aged 6 weeks to 59 months in an outbreak response campaign in The Gambia: an observational cohort studyAdedapo O Bashorun, Larry Kotei, Ousubie Jawla, et al.
Lancet (London, England)|February 25, 2024
Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trialMagnus Ochoge, Ahmed Cherno Futa, Ama Umesi, et al.
The Lancet. Global Health|July 2, 2016
Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The GambiaEd Clarke, Yauba Saidu, Jane U Adetifa, et al.
Lancet (London, England)|May 2, 2024
A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trialIkechukwu Adigweme, Mohammed Yisa, Michael Ooko, et al.
Gates Open Research|March 29, 2023
Circulation of respiratory viruses during the COVID-19 pandemic in The GambiaSheikh Jarju, Elina Senghore, Helen Brotherton, et al.
Cell Reports. Medicine|January 14, 2022
Prior upregulation of interferon pathways in the nasopharynx impacts viral shedding following live attenuated influenza vaccine challenge in childrenAndré G Costa-Martins, Karim Mane, Benjamin B Lindsey, et al.
Vaccine|December 27, 2025
Maternal iron status and total immunoglobulin-G influence transplacental antibody transfer across eight diverse geographical settingsKaren S Tiley, Hinke Ten Hulscher-van Overbeek, Andrew E Armitage, et al.
Cell Reports. Medicine|March 4, 2022
Erratum: Prior upregulation of interferon pathways in the nasopharynx impacts viral shedding following live attenuated influenza vaccine challenge in childrenAndré G Costa-Martins, Karim Mane, Benjamin B Lindsey, et al.
The Lancet. Microbe|January 20, 2025
Interactions between live attenuated influenza vaccine and nasopharyngeal microbiota among children aged 24-59 months in The Gambia: a phase 4, open-label, randomised controlled trialChikondi Peno, Ya Jankey Jagne, Melanie Clerc, et al.
Pageof 6